[Evaluation of erythropoiesis under the influence of recombinant human erythropoietin (R-EPO) in dialyzed patients]. 1991

A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
Kliniki Chorób Nerek Instytutu Chorób Wewnetrznych.

5 deeply anemic (Hb less than 8 g/dl, Ht less than 25%) dialyzed patients with chronic renal failure were treated during four months with r-Epo. Blood cells morphological parameters were estimated using hematological autoanalyser Technicon H1. Satisfactory increase of the Hb levels and RBC counts were observed in 4 patients, in one the improvement was insignificant. We observed three types of response to r-Epo treatment: 1) macrocytic type, 2) hypochromic type, and 3) non-hypochromic type, without lasting macrocytosis. Our results suggest that type of erythropoiesis depends on other active biological substances (iron, folic acid, vit. B12) necessary for correcting erythropoiesis. r-Epo administration appeared to be a safe and effective method of anaemia treatment in dialyzed patients. Its administration eliminated blood transfusion for six months.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004920 Erythropoiesis The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction. Erythropoieses
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
November 1988, Polskie Archiwum Medycyny Wewnetrznej,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
October 1993, Wiadomosci lekarskie (Warsaw, Poland : 1960),
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
January 1994, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
January 1994, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
June 1990, Revista medica de Chile,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
February 2000, Angiology,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
January 1994, Clinical and experimental rheumatology,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
September 2004, Journal of pharmaceutical and biomedical analysis,
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
February 1992, Professional nurse (London, England),
A Debska-Slizień, and J Kabata, and B Rutkowski, and D Ciesielski, and E Jankowska-Gan, and A Manitius
January 1999, Praxis,
Copied contents to your clipboard!